This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Deerfield, IL, Baxter International Inc. (BAX) is a global medical technology company. However, the company spun off its biopharmaceuticals segment into an independent entity – Baxalta Inc. Following the spinoff, the company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions.
CVS Health (CVS) Down on Prevailing Risks, Tepid Guidance
by Zacks Equity Research
In Dec 19, 2016, we issued an updated research report on Rhode Island-based pharmacy retail giant CVS Health Corp. (CVS)
Zimmer Biomet (ZBH): Spine Group Solid, Q3 Results a Drag
by Zacks Equity Research
On Dec 19, we issued an updated research report on Warsaw, IN-based Zimmer Biomet Holdings Inc. (ZBH).
Align Technology Hits 52-Week High on Q3 & Dental Strength
by Zacks Equity Research
Share price of San Jose, CA-based Align Technology, Inc. (ALGN) scaled a new 52-week high of $102.1 on Dec 19, finally closing a bit lower at $100.3.
Bruker (BRKR) Buys Active Spectrum to Boost MRI Business
by Zacks Equity Research
Bruker Corporation (BRKR) recently announced the acquisition of Active Spectrum Inc., a manufacturer of innovative benchtop micro-ESR spectroscopy systems.
Hill Rom Gains on Solid Q4, Buyouts & Product Launches
by Zacks Equity Research
On Dec 16, we issued an updated research report on Batesville, IN-based medical device manufacturer, Hill-Rom Holdings, Inc. (HRC).
Hologic (HOLX) to Divest Blood Screening Business to Grifols
by Zacks Equity Research
Hologic, Inc. (HOLX) recently inked a deal to divest its stake in the blood screening business.
CVS Health Revises View for 2016 & 2017, Declares Dividend
by Zacks Equity Research
CVS Health Corporation (CVS) recently announced strategies to drive long-term growth and shareholders' value.
CVS Health Introduces Transform Diabetes Care Program
by Zacks Equity Research
CVS Health Corporation (CVS) recently unveils Transform Diabetes Care Program which will help the company's PBM clients improve health outcome of diabetic patients.
Baxter (BAX) to Acquire India-Based Claris Injectables
by Zacks Equity Research
Baxter International Inc. (BAX), a global medical technology company, has signed a definitive agreement to acquire Claris Lifesciences Limited???s subsidiary Claris Injectables Limited for almost $625 million.
Hologic Hits 52-Week High on Q4 Earnings & Solid Prospects
by Zacks Equity Research
Share price of Bedford, MA-based Hologic Inc. (HOLX) reached a new 52-week high of $41.01 on Dec 14, finally closing a tad lower at $40.79.
Zimmer Biomet (ZBH) Reveals Positive Hip Arthroplasty Data
by Zacks Equity Research
Zimmer Biomet Holdings, Inc. (ZBH) declared that, the National Joint Registry (NJR) for England, Wales, Northern Ireland and the Isle of Man documented favorable outcome on its Trabecular Metal Cups.
Zimmer Biomet (ZBH) Launches PrimaGen Advanced Allograft
by Zacks Equity Research
Zimmer Biomet Holdings, Inc. (ZBH) recently launched PrimaGen Advanced Allograft which has been designed to be used as an allogeneic bone graft substitute.
Boston Scientific Acquires Neovasc to Boost Heart Business
by Zacks Equity Research
Boston Scientific Corporation (BSX) recently completed the acquisition of specialty medical device company Neovasc Inc.'s (NVCN) tissue processing technology.
Inovalon (INOV) Cuts 2016 Revenue and Earnings Guidance
by Zacks Equity Research
Inovalon Holdings (INOV), lowered its revenue and earnings guidance for full-year 2016.
Haemonetics' Plasma Group Impresses, Blood Center a Drag
by Zacks Equity Research
On Dec 12, we issued an updated research report on Braintree, MA-based Haemonetics Corporation (HAE).
Align Up on Balanced Growth, Expansion of Invisalign Teen
by Zacks Equity Research
On Dec 9, 2016, we issued an updated research report on California-based Align Technology Inc. (ALGN).
Genomic Health Posts Impressive Data for Oncotype DX Test
by Zacks Equity Research
Genomic Health Inc. (GHDX) recently unveiled positive findings of its Oncotype DX test in individualizing breast cancer treatment decisions for patients at various stages of the disease.
Zacks.com featured highlights: Baxter International, MAM Software Group, Advanced Energy Industries, Apricus Biosciences and Copart
by Zacks Equity Research
Zacks.com featured highlights: Baxter International, MAM Software Group, Advanced Energy Industries, Apricus Biosciences and Copart
Amedisys Down on Dismal Quarter, Reimbursement Headwind
by Zacks Equity Research
On Dec 8, we issued an updated research report on Baton Rouge, LA-based Amedisys Inc. (AMED).
5 Efficient Stocks to Buy for Superlative Returns
by Zacks Equity Research
Investors seeking impressive returns irrespective of market conditions may consider adding stocks with favorable efficiency levels to their portfolios.
Haemonetics Introduces Upgraded NextGen DMS 4 Software
by Zacks Equity Research
Haemonetics Corporation (HAE) recently unveiled upgraded NextGen DMS (Donor Management System) to augment plasma collection center operations.
Henry Schein Buys Stake in Marrodent; Spurs Polish Foothold
by Zacks Equity Research
Henry Schein (HSIC) has recently completed its earlier announced purchase of 80% ownership of Marrodent.
Steris Poor Q2 Disappoints, Synergy Health Raises Hope
by Zacks Equity Research
On Dec 7, we issued an updated research report on OH-based STERIS plc (STE).
Masimo (MASI) Hits 52-Week High on Solid Growth Prospects
by Zacks Equity Research
Share price of Irvine, CA-based Masimo Corporation (MASI) reached a new 52-week high of $63.45 on Dec 7, finally closing a tad lower at $62.17.
Henry Schein's Q3 Results Impress, Pricing Pressure a Drag
by Zacks Equity Research
On Dec 6, we issued an updated research report on Melville, NY-based Henry Schein Inc. (HSIC).